



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2017-18
Date: 13th November, 2017

To,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
BSE CODE - 524348
BSE ID - AARTIDRUGS

National Stock Exchange of India
Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051
NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting held today i.e. 13th November, 2017 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Monday, 13th November, 2017 had *inter-alia* considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter & Half year ended 30th September, 2017. Accordingly, please find enclosed herewith Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter & Half year ended on 30th September, 2017 along with the report of the Statutory Auditors.

The meeting commenced at 12 noon and concluded at 13.50 p.m.

The above is for your kind information and records. You are requested to acknowledge the receipt.

Thanking you,
Yours faithfully,
For Aarti Drugs Limited

Vibhav S. Ranade
Company Secretary & Compliance Officer
M. No. A35284





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEP, 2017

(Rs. in lakhs except for share data)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Period Ended			Quarter Ended			Period Ended		
		30th Sep 2017 (Audited)	30th Jun 2017 (Audited)	30th Sep 2016 (Audited)	30th Sep 2017 (Audited)	30th Sep 2016 (Audited)	31st Mar 2017 (Audited)	30th Sep 2017 (Audited)	30th Jun 2017 (Audited)	30th Sep 2016 (Audited)	30th Sep 2017 (Audited)	30th Sep 2016 (Audited)	31st Mar 2017 (Audited)
I	Revenue from operations	28,820	24,826	31,332	53,645	60,817	1,18,593	31,927	27,720	34,215	59,647	65,763	1,28,808
II	Other income	8	8	50	14	63	353	8	7	58	15	98	400
III	Total Income (I + II)	28,827	24,832	31,382	53,660	60,880	1,18,947	31,935	27,726	34,273	59,662	65,859	1,29,208
IV	Expenses :												
	(a) Cost of materials consumed	16,295	18,536	18,975	34,830	38,533	67,806	17,111	20,617	20,521	37,728	41,471	74,020
	(b) Purchase of stock-in-trade	443	824	438	1,267	873	1,830	972	1,137	1,155	2,109	1,944	4,068
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,751	(5,389)	(900)	(3,638)	(3,317)	366	2,052	(5,533)	(995)	(3,481)	(3,600)	(43)
	(d) Excise duty/taxes on goods sold	-	1,920	2,667	1,920	5,252	9,721	-	1,894	2,703	1,894	5,102	9,291
	(e) Employee benefits expense	1,236	1,189	1,184	2,425	2,333	4,748	1,426	1,360	1,322	2,786	2,583	5,283
	(f) Finance costs	760	846	832	1,806	1,780	3,448	803	694	878	1,697	1,874	3,642
	(g) Depreciation and amortisation expense	949	926	930	1,875	1,850	3,669	1,006	981	974	1,987	1,936	3,846
	(h) Other expenses	4,690	4,429	4,258	9,119	8,062	16,581	5,111	4,705	4,452	9,817	8,432	17,500
	Total expenses (IV)	25,124	23,280	28,382	49,404	55,366	1,08,169	28,482	26,054	31,011	54,537	59,742	1,17,607
V	Profit before exceptional items and tax (III - IV)	2,703	1,552	3,000	4,255	5,514	10,778	3,453	1,672	3,262	5,125	6,117	11,601
VI	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
VII	Profit before tax (V - VI)	2,703	1,552	3,000	4,255	5,514	10,778	3,453	1,672	3,262	5,125	6,117	11,601
VIII	Tax Expenses :												
	Provision for taxation - Current	700	370	850	1,070	1,490	2,753	865	398	906	1,262	1,620	2,913
	- MAT credit entitlement	-	-	-	-	-	-	4	(4)	-	-	-	-
	- Earlier year	-	-	-	-	-	(203)	-	-	-	-	-	(203)
	Provision for deferred taxation	200	125	140	325	280	680	225	140	148	365	296	711
	Total tax expenses (VIII)	900	495	990	1,395	1,770	3,230	1,093	534	1,055	1,627	1,916	3,421
IX	Profit/(Loss) for the period from continuing operations (VII - VIII)	1,803	1,057	2,010	2,860	3,744	7,548	2,360	1,138	2,207	3,498	4,201	8,180
X	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XI	Tax expenses of discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	Profit/(Loss) from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX - XII)	1,803	1,057	2,010	2,860	3,744	7,548	2,360	1,138	2,207	3,498	4,201	8,180
XIV	Other Comprehensive Income	-	-	(32)	-	(30)	(109)	-	-	(32)	-	(30)	(109)
XV	Total Comprehensive Income for the period (XIII+XIV)	1,803	1,057	1,978	2,860	3,713	7,439	2,360	1,138	2,175	3,498	4,171	8,071
XVI	Paid up equity share capital (face value of Rs.10 each)	2,386	2,386	2,422	2,386	2,422	2,386	2,386	2,386	2,422	2,386	2,422	2,386
XVII	Earning per equity share (in Rs.) (not annualised)												
	(1) Basic	7.56	4.43	8.30	11.99	15.46	30.78	9.89	4.77	9.11	14.66	17.35	33.40
	(2) Diluted	7.56	4.43	8.30	11.99	15.46	30.78	9.89	4.77	9.11	14.66	17.35	33.40

For AARTI DRUGS LIMITED

Prakash M. Patil
(Chairman & Managing Director)

Place: Mumbai
Date: 13th November, 2017



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED				
STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEP, 2017				
(Rs. in lacs)				
Particulars	Standalone		Consolidated	
	30th Sep 2017	31st Mar 2017	30th Sep 2017	31st Mar 2017
ASSETS				
1 Non - Current Assets				
Property, Plan and Equipment	55,541	53,632	59,453	57,501
Intangible assets	525	600	536	608
Capital work - in - progress	1,926	1,413	1,941	1,428
Financial Assets				
Investments	1,842	1,842	1,194	1,194
Other Non- Current Assets	786	649	811	703
Total Non- Current Assets	60,620	58,137	63,935	61,434
2 Current Assets				
Inventories	21,687	18,875	23,784	20,963
Financial Assets				
(i) Trade receivable	30,095	27,827	31,083	29,681
(ii) Cash and cash equivalents	482	400	521	417
(iii) Other Current Financial Assets	3,472	1,834	3,568	1,979
Other current assets	4,102	4,011	4,498	4,102
Total Current Assets	59,838	52,948	63,456	57,142
TOTAL ASSETS	1,20,458	1,11,085	1,27,391	1,18,577
EQUITY AND LIABILITIES				
1 EQUITY				
Share Capital	2,386	2,386	2,386	2,386
Other Equity	38,884	36,311	40,858	37,628
Total Equity	41,270	38,697	43,243	40,013
LIABILITIES				
2 Non-current liabilities				
Financial Liabilities				
(i) Borrowings	17,919	18,745	19,209	20,155
(ii) Other financial liability	1,492	1,242	1,492	1,488
Provisions	1,045	741	1,091	714
Deferred tax liabilities (Net)	6,943	6,618	7,015	6,650
Total of Non current liabilities	27,399	27,345	28,806	29,007
3 Current liabilities				
Financial Liabilities				
(i) Borrowings	27,939	22,957	29,220	24,466
(ii) Trade payables	18,944	17,030	20,632	19,697
Provisions	1,150	1,189	1,310	1,276
Other current liabilities	3,757	3,866	4,179	4,117
Total of current liabilities	51,789	45,043	55,342	49,556
TOTAL EQUITY AND LIABILITIES	1,20,458	1,11,085	1,27,391	1,18,577

Notes :

- The above results for the quarter and period ended 30th September, 2017 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13th November, 2017.
- Results for the quarter and period year ended 30th september 2017 are in compliance with the Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. Consequently results for quarter and Period ended 30th September, 2016 and previous year ended 31st March 2017 have been restated to comply with Ind-AS to make them comparable.
- Post the applicability of GST with effect from 1st July 2017, Sales are disclosed net of GST. Accordingly, the Gross Sales figures for the quarter and Period ended 30th September 2017 are not comparable with the sales figures depicted in the results for the previous periods.
- Company is operating as a single segment company, engaged in pharmaceutical business.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

For AARTI DRUGS LIMITED



A. Reconciliation of the net profit to those reported under previous Generally Accepted Accounting Principles(GAAP) are summarised as follow :

(Rs in Lakhs)

Particulars	Note No.	Standalone			Consolidated		
		3 Months Ended	6 Months Ended	12 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
		30th Sep 2016 (Audited)	30th Sep 2016 (Audited)	31st Mar 2017 (Audited)	30th Sep 2016 (Audited)	30th Sep 2016 (Audited)	30th Mar 2017 (Audited)
Net Profit as per previous IGAAP		2,010	3,744	7,424	2,207	4,201	8,056
Other Comprehensive Income (Net of tax)	3	(32.26)	(30.49)	14.89	(32.26)	(30.49)	14.89
Total Comprehensive Income as per Ind-AS		1,978	3,713	7,439	2,175	4,171	8,071

B. Reconciliation of Equity as reported under previous Generally Accepted Accounting Principles (GAAP) are summarised as follows:

Particulars	Note No.	Equity as last reported as at 31st March,2017 (Standalone)	Equity as last reported as at 31st March,2017 (Consolidated)
Equity reported as per previous GAAP		39,755	41,072
Impact of measuring Investments at Fair Value Through Other Comprehensive Income (Net of tax)	3	666	666
Impact of Deffered Tax & MAT Credit		(1,724)	(1,724)
Equity reported as per Ind-AS		38,697	40,013

Notes:

- Property, Plant and Equipment were carried in the statement of financial position prepared under previous GAAP as at 31st March,2016. The Company has elected to regard such carrying amount as deemed cost at the date of transition i.e. 1st April,2016
- Under previous GAAP, non current Investments were stated at cost. Where applicable, provision was made to recognise a decline, other than temporary, in valuation of such Investments. Under Ind-AS, financial assets in equity instruments have been classified as Fair Value though Other comprehensive Income (FVTOCI) through as irrevocable election at the date of transition.
- Under the previous GAAP, cost relating to post employment benefit obligations including actuarial gain/losses were recognised in Profit & Loss. Under Ind AS, actuarial gain/losses on the net defined benefit liability are recognised in other comprehensive income instead of profit & loss.

Benefice Business House, 3rd Level,
126, Mathuradas Mills Compound,
N. M. Joshi Marg, Lower Parel (W),
Mumbai - 400013, India.

T : +91 22 3321 3737
F : +91 22 3321 3838
E : reachus@gbcaindia.com
W : www.gbcaindia.com



**Auditor's Report on Quarterly Standalone Financial Results of AARTI DRUGS LIMITED
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To
The Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly standalone financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended September 30, 2017 and year to date results for the period April 01, 2017 to September 30, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting", prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

The comparative audited standalone financial statements for the quarter and six months ended 30th September 2016, year ended 31st March 2017 and Quarter ended 30th June 2017 including the reconciliation of profit under IND AS of the corresponding quarter ended 30th September 2016 and the year to date from 1st April 2016 to 30th September 2016 with the profit reported under previous GAAP, included in this statement have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" whose report dated 9th November 2016 and 23rd May 2017 and 18th August 2017 respectively have expressed unmodified opinion on those audited financial statements, as



adjusted for the differences in the accounting principles adopted by the Company on transition to the Ind AS which have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" and has been relied upon by us for the purpose of our audit of the Statement.

In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:

- (i) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- (ii) give a true and fair view of the net profit, total comprehensive income and other financial information for the quarter ended September 30, 2017 as well as the year to date results for the period from April 01, 2017 to September 30, 2017.

For **GBCA & Associates**

Chartered Accountants

Firm Registration No: - 103142W



Yogesh Amal

Partner

M. No. 111636

Place: Mumbai

Date: 13th November, 2017

Benefice Business House, 3rd Level,
126, Mathuradas Mills Compound,
N. M. Joshi Marg, Lower Parel (W),
Mumbai - 400013, India.

T : +91 22 3321 3737
F : +91 22 3321 3838
E : reachus@gbcaindia.com
W : www.gbcaindia.com



**Auditor's Report on Quarterly Consolidated Financial Results of AARTI DRUGS LIMITED
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To
The Board of Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED ("the Company") for the quarter ended September 30, 2017 and the year to date consolidated financial results for the period from April 1, 2017 to September 30, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly consolidated financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid Indian Accounting Standard (IND AS) 34 "Interim Financial Reporting", prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit financial statements/financial information of only subsidiary whose financial statement/financial information reflect total assets of Rs.9,275.21 Lakhs as at 30th September 2017, total revenues of Rs.4,244.94 lakhs and Rs.7,556.18 lakhs for the quarter ended and for six months ended 30th September 2017, as considered in the consolidated financial statements. These financial statements/ financial information have been audited by other auditor whose report have been furnished to us and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of its subsidiary is based solely on the report of the other auditor.



The comparative audited Consolidated financial statements for the quarter and six months ended 30th September 2016, year ended 31st March 2017 and Quarter ended 30th June 2017 including the reconciliation of profit under IND AS of the corresponding quarter ended 30th September 2016 and the year to date from 1st April 2016 to 30th September 2016 with the profit reported under previous GAAP, included in this statement have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" whose report dated 9th November 2016 and 23rd May 2017 and 18th August 2017 respectively have expressed unmodified opinion on those audited financial statements, as adjusted for the differences in the accounting principles adopted by the Company on transition to the Ind AS which have been audited by predecessor auditor "M/s Gokhale & Sathe, Chartered Accountants" and has been relied upon by us for the purpose of our audit of the Statement.

In our opinion and to the best of our information and according to the explanations given to us these quarterly and year to date consolidated financial results:

- (i) include the quarterly and year to date financial results of its only subsidiary, Pinnacle Life Science Private Limited
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5,2016; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended September 30, 2017 as well as the year to date results for the period from April 1, 2017 to September 30, 2017.

For GBCA & Associates
Chartered Accountants
Firm Registration No: - 103142W



Yogesh Amal
Partner
M. No. 111636



Place: Mumbai
Date: 13th November, 2017